Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE IN PLASTIC CONTAINER versus GUAIFENESIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE IN PLASTIC CONTAINER versus GUAIFENESIN.
AMMONIUM CHLORIDE IN PLASTIC CONTAINER vs GUAIFENESIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant